Quant Manufacturing Fund
Direct · GrowthAI Summary
Quant Manufacturing Fund has outperformed the NIFTY 50 across all measured periods, with a 3Y lump-sum CAGR of 15.68% versus the benchmark's 4.9%, generating 10.92% alpha over 3Y. However, its SIP XIRR of 11.27% over 3Y trails the category average of 16.31%, suggesting the fund has underperformed sectoral/thematic peers on a SIP basis. Calendar year returns show volatility, ranging from 25.39% in 2023 to -5.18% in 2025.
The fund carries a beta of roughly 1.09 against the NIFTY 50, with upside capture above 110% but downside capture near 98%, indicating it amplifies gains while offering limited downside protection. Two drawdown events exceeding 10% have occurred, and the maximum drawdown duration of 549 days with no recorded recovery highlights prolonged recovery risk. The 3Y Calmar ratio of 0.59 reflects moderate risk-adjusted efficiency relative to the fund's strong absolute returns.
The portfolio is highly concentrated with only 16 total holdings, and the top 10 positions account for over 83% of NAV, led by Aurobindo Pharma (9.94%), BHEL (9.47%), and Adani Enterprises (9.12%). Sector exposure is dominated by Pharmaceuticals & Biotechnology at 24% and Electrical Equipment at 15.5%, with meaningful allocations to Adani group companies across three of the top ten holdings. This concentrated structure magnifies both potential returns and single-stock or group-level risk.
The fund's 1Y SIP XIRR of 11.99% modestly beats the category average of 10.72%, but its 3Y XIRR of 11.27% falls well short of the category's 16.31%, indicating weaker consistency versus peers over longer horizons. Lump-sum performance has been stronger, with a 3Y rolling mean of 17.59%. Investors comparing options within the sectoral/thematic category should note the fund's mixed relative record depending on investment mode.
This fund suits aggressive investors with high risk tolerance who want targeted exposure to India's manufacturing, pharma, and energy themes, and who can tolerate concentrated portfolio swings. A time horizon of at least 5-7 years is advisable given the extended drawdown duration and thematic cyclicality. It should be treated as a satellite allocation within a diversified portfolio rather than a core holding.
- Consistent alpha over the NIFTY 50 across all periods from 1Y to 15Y, including 10.92% alpha over 3Y
- Strong upside capture above 110% in all measured periods, amplifying benchmark gains
- Low expense ratio of 0.71% for a sectoral/thematic direct plan
- 3Y SIP XIRR of 11.27% significantly trails the category average of 16.31%, indicating underperformance versus thematic peers
- Extreme concentration with only 16 holdings, over 83% of NAV in the top 10, and heavy exposure to Adani group companies
Generated on 13-10-2026, 3:11 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.23 L | 11.6% | -35.7% | 83.1% |
| 3 Years | ₹36.00 L | ₹42.82 L | 11.7% | 6.0% | 15.2% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 11.6% | 14.3% | 10.7% | -2.6% |
| 3 Years | 11.7% | 11.0% | 16.3% | +0.7% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 9.8% | 3.0% | -19.4% | 75.6% | 0.14 | 0.32 | 54% | — | — |
| 3 Years | 17.2% | 16.9% | 14.6% | 20.5% | 5.87 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +18.06 | 1.03 | 104.2% | 82.1% | 8.1% | -9.5% |
| 3 Years | +9.29 | 1.07 | 108.3% | 96.8% | 14.7% | 5.5% |
| 5 Years | +7.27 | 1.07 | 111.2% | 96.7% | 10.7% | 3.6% |
| 7 Years | +5.22 | 1.07 | 111.2% | 96.7% | 7.5% | 2.6% |
| 10 Years | +3.74 | 1.07 | 111.2% | 96.7% | 5.2% | 1.8% |
| 12 Years | +3.17 | 1.07 | 111.2% | 96.7% | 4.3% | 1.5% |
| 15 Years | +2.61 | 1.07 | 111.2% | 96.7% | 3.5% | 1.2% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Aurobindo Pharma Limited | 9.94% |
| 2 | Bharat Heavy Electricals Ltd | 9.47% |
| 3 | Adani Enterprises Limited | 9.12% |
| 4 | Reliance Industries Ltd. | 8.93% |
| 5 | Ador Welding Limited | 8.47% |
| 6 | Lloyds Metals And Energy Limited | 8.08% |
| 7 | Adani Green Energy Limited | 7.85% |
| 8 | Zydus Wellness Ltd | 7.60% |
| 9 | Divi's Laboratories Ltd. | 7.45% |
| 10 | Ravindra Energy Limited | 6.02% |